WELCOME TO THE NEW DR. GOODENOWE RESEARCH INSTITUTE
Dr. Goodenowe’s expanded research facilities will enable him and his collaborators worldwide to understand disease in order to restore health, and develop meaningful solutions for achieving and maintaining vitality well past age 100.
Our new, 10,000+ square foot facility is being custom built by Dr. Goodenowe to house his advanced biochemistry technologies and supportive infrastructure.
Dr. Goodenowe’s laboratory is his playground. Here he dives into the complex biochemical systems of our lives and delivers real solutions for longevity.
The biochemistry technology is now installed (and more coming!).
Advanced MRI technology is in development.
On-site doctor training is ready soon.
And in-person services are almost complete.
Population Health
The real human population is messy. Population health is about designing and executing clinical trials for the real world and for real people living normal lives. Population health is about changing disease incidence rates and improving functions as we age.
My research focuses on real world solutions for every person. “One size fits all” fits nobody.
Population Health
The real human population is messy. Population health is about designing and executing clinical trials for the real world and for real people living normal lives. Population health is about changing disease incidence rates and improving functions as we age.
My research focuses on real world solutions for every person. “One size fits all” fits nobody.
I have had the good fortune of observing firsthand the significant, clinical benefits in my patients with neurodegenerative disorders for whom I’ve prescribed plasmalogen therapy."
BREAKING ALZHEIMER’S
Dr. Goodenowe’s book Breaking Alzheimer’s: A 15 Year Crusade to Expose the Cause and Deliver the Cure launched in 2021, where he outlines the story of plasmalogens.
"A paradigm-altering view of Alzheimer’s."
BREAKING RCDP
RCDP is a rare childhood genetic disease. Affected children do not have plasmalogens. As part of Dr. Goodenowe’s Childhood Peroxisomal Disease Foundation, where he offers his biochemical research strategies free of charge to affected families, Dr. Goodenowe is specifically breaking down RCDP (a type of peroxisomal disease).
- Autism
- Multiple Sclerosis
- Dementia
- Alzheimer's Disease
- Parkinson's Disease
- Colon Cancer
- Liver Cancer
- Hepatitis Cirrhosis
- Aging
- Pancreatic Cancer
- Gastric Cancer
- ALS
- Esophageal Cancer
- Breast Cancer
- Cervical Cancer
- Endometrial Cancer
- Prostate Cancer
RESEARCH COLLABORATIONS
PATENTS
Issued September 19, 2006 Canada 2298181
Biomarkers Useful for Diagnosing Multiple Sclerosis and Other Neurological Disorders, and Methods Thereof
Methods for the Diagnosis and Risk Assessment of Plasmalogen Deficiency Mediated Diseases of Aging
Methods for the Diagnosis of Colorectal Cancer and Ovarian Cancer By the Measurement of Vitamin E-related Metabolites
Issued: Canada, Israel, Australia, Japan, United States. Pending: Hong Kong.
articles
- Plasmalogen deficiency and neuropathology in Alzheimer’s disease: Causation or coincidence? Alzheimer’s & Dementia TRCI 5: Doi 10.1016/j.trci.2019.08.003
- Relation of Serum Plasmalogens and APOE Genotype to Cognition and Dementia in Older Persons in a Cross-Sectional Study. Brain Sci 9: Doi 10.3390/brainsci9040092
- Metabolic dysfunctions in multiple sclerosis: implications as to causation, early detection, and treatment, a case control study. BMC neurology, 15, 154. doi:10.1186/s12883-015-0411-4
- Metabolic system alterations in pancreatic cancer patient serum: potential for early detection. BMC Cancer 13: 416 Doi 10.1186/1471-2407-13-416
- Circulating plasmalogen levels and Alzheimer Disease Assessment Scale-Cognitive scores in Alzheimer patients. J Psychiatry Neurosci 35: 59-62
- Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer’s disease and dementia. J Lipid Res 48: 2485-2498 Doi 10.1194/jlr.P700023-JLR200
- Pancreatic cancer serum biomarker PC-594: Diagnostic performance and comparison to CA19-9. World J Gastroenterol 21(21): 6604-6612
- Low-serum GTA-446 anti-inflammatory fatty acid levels as a new risk factor for colon cancer. Int J Cancer 132: 355-362 Doi 10.1002/ijc.27673
- Metabolic system alterations in pancreatic cancer patient serum: potential for early detection. BMC Cancer 2013, 13:416
- Human serum-derived hydroxy long-chain fatty acids exhibit anti-inflammatory and anti-proliferative activity. J Exp Clin Cancer Res 30: 59 Doi 10.1186/1756-9966-30-59
- Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med 8: 13 Doi 10.1186/1741-7015-8-13
- Reduction of novel circulating long-chain fatty acids in colorectal cancer patients is independent of tumor burden and correlates with age. BMC Gastroenterol 10: 140 Doi 10.1186/1471-230X-10-140
- Serum Metabolite Profiling for the Detection of Pancreatic Cancer: Results of a Large Independent Validation Study. Pancreas. 2016;45:1418-23.
- Metabolic system alterations in pancreatic cancer patient serum: potential for early detection. BMC Cancer. 2013;13:416.
- Plasmalogen deficiency and neuropathology in Alzheimer’s disease: Causation or coincidence? Alzheimer’s & Dementia TRCI 5: Doi 10.1016/j.trci.2019.08.003
- Relation of Serum Plasmalogens and APOE Genotype to Cognition and Dementia in Older Persons in a Cross-Sectional Study. Brain Sci 9: Doi 10.3390/brainsci9040092
- Plasmalogen Augmentation Reverses Striatal Dopamine Loss in MPTP Mice. PLoS One. 2016 Mar 9;11(3):e0151020. doi: 10.1371/journal.pone.0151020.
- Metabolic dysfunctions in multiple sclerosis: implications as to causation, early detection, and treatment, a case control study. BMC neurology, 15, 154. doi:10.1186/s12883-015-0411-4
- Plasmalogen precursor analog treatment reduces levodopa-induced dyskinesias in parkinsonian monkeys. Behav Brain Res. 2015 Jun 1;286:328-37. doi: 10.1016/j.bbr.2015.03.012.
- Oral bioavailability of the ether lipid plasmalogen precursor, PPI-1011, in the rabbit: a new therapeutic strategy for Alzheimer’s disease. Lipids in health and disease, 10, 227. doi:10.1186/1476-511X-10-227
